Weekly Etoposide, Epirubicin, Cisplatin, 5-Fluorouracil and Leucovorin for Advanced Gastric Cancer
Author Information
Author(s): KH Chi, Y Chao, WK Chan, SS Lo, SY Chen, SH Yen, KY Chen, CW Wu, SD Lee, WY Lui
Primary Institution: Veterans General Hospital-Taipei, National Yang-Ming University, Taiwan
Hypothesis
Weekly administration of EEPFL chemotherapy will improve the therapeutic index in advanced gastric cancer treatment.
Conclusion
Weekly EEPFL chemotherapy is an effective regimen with tolerable toxicities for advanced gastric cancer.
Supporting Evidence
- 26% of patients showed complete response and 45% partial response.
- The overall response rate was 71%.
- Median survival was 10 months.
- Grade 4 leucopenia occurred in 1% of cycles.
- Three patients remained disease-free and alive at 24+, 26+, and 34+ months.
Takeaway
Doctors tested a new way to give chemotherapy to people with advanced stomach cancer, and it worked well with fewer side effects.
Methodology
Patients with advanced gastric cancer received a weekly regimen of EEPFL chemotherapy, and their responses and side effects were monitored.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
Median age was 69 years, with 37 males and 5 females.
Statistical Information
P-Value
0.03
Confidence Interval
58-84
Statistical Significance
p=0.03
Want to read the original?
Access the complete publication on the publisher's website